4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Income from Continuing Operations of 68756000.0 for Q1 2026, down 43.13% year-over-year from 120890472.29 in Q1 2025, and down 454.07% quarter-over-quarter from 19419000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Income from Continuing Operations data on file, last reported at 68756000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 68756000.0, down 43.13% year-over-year; the trailing twelve-month figure through Mar 2026 was 160789000.0 (up 8.87% YoY), and the FY2025 annual result was 140072000.0, up 12.89% from the prior year.
- Income from Continuing Operations retreated to 68756000.0 in Q1 2026 per FDMT's latest filing, from 19419000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 19419000.0 in Q4 2025 and troughed at 68756000.0 in Q1 2026.
- A 5-year average of 33984470.59 and a median of 32272000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 334.17% in 2024, then soared 139.11% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 27382000.0 in 2022, then fell by 17.86% to 32272000.0 in 2023, then sank by 53.85% to 49650000.0 in 2024, then soared by 139.11% to 19419000.0 in 2025, then plunged by 454.07% to 68756000.0 in 2026.
- Business Quant data shows FDMT's Income from Continuing Operations at 68756000.0 in Q1 2026, 19419000.0 in Q4 2025, and 56855000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -68.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.76 Mn |
| Dec 31, 2025 | 19.42 Mn |
| Sep 30, 2025 | -56.86 Mn |
| Jun 30, 2025 | -54.60 Mn |
| Mar 31, 2025 | -48.04 Mn |
| Dec 31, 2024 | -49.65 Mn |
| Sep 30, 2024 | -43.84 Mn |
| Jun 30, 2024 | -34.91 Mn |
| Mar 31, 2024 | -32.39 Mn |
| Dec 31, 2023 | -32.27 Mn |
| Sep 30, 2023 | -10.10 Mn |
| Jun 30, 2023 | -29.62 Mn |
| Mar 31, 2023 | -28.66 Mn |
| Dec 31, 2022 | -27.38 Mn |
| Sep 30, 2022 | -25.70 Mn |
| Jun 30, 2022 | -28.09 Mn |
| Mar 31, 2022 | -26.29 Mn |
| Dec 31, 2021 | -25.08 Mn |
| Sep 30, 2021 | -22.23 Mn |
| Jun 30, 2021 | -7.59 Mn |